Clinical Trial Search

Primary: Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP) — 163.9; 163.3; 140.9; 144.4 mmHg

Primary: Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7 — -28.5; -37.0 mmHg — p=<0.0001

Primary: Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen — 86.12 Percentage of…

Primary: Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8) — -31.37; -27.99; -30.77; -37.92 mmHg

Primary: Change From Baseline in Trough Seated Systolic Blood Pressure (SBP) at Week 8 — -47.5; -36.9; -43.2 mmHg (millimeters of mercury) — p=<0.0001

Primary: The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal…

Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg

Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg

Primary: Number of Participants Who Died Within 7 Days After Discharge From the Emergency Department — 0; 0 participants

Primary: Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16 — -11.16; -9.13; -8.10; -5.66 mm Hg — p=<0.0001

Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint — -10.3; -6.6 mmHg

Primary: Change in Mean Trough Sitting Diastolic Blood Pressure — -11.16; -10.45 mm Hg — p=0.2648

Primary: Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure. — -37.6; -38.2; -31.5 mmHg — p=<0.001

Primary: SBP — 130.2; 128.8 mm Hg

Primary: Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg — -6.1; -7.1; -8.9 mm Hg — p=0.1187

Primary: Mean Sitting Systolic Blood Pressure (msSBP) — -37.72; -30.63 mm Hg

Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants

Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg

Primary: Percentage of Patients With Controlled Blood Pressure (<140/90 mmHg) — 3083 Participants

Primary: Adverse Events — 1; 1; 1; 1 participants

Primary: Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study — -3.12 mmHg

Primary: Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis) — -28.9; -15.9; -15.1 mmHg…

Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg

Primary: DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean — -12.76; -23.82 mmHg

Primary: Mean Systolic Blood Pressure During Hour After Study Drug — 147; 152 mmHg

Primary: Change in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) — -9.1; -8.0 mmHg — p=0.205

Primary: Mean Systolic Blood Pressure (SBP) Difference at 6 Months Post-intervention Compared to Usual Care. — -9.2; -14.0 mmHg

Primary: Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure — -35.1; -29.5; -37.8; -32.8 mmHg — p=<0.001

Primary: Change in Nocturnal Systolic Blood Pressure Level — -12.6; -17.5 mmHg

Primary: Change From Baseline to Week 8 in Mean Sitting Systolic Blood Pressure (msSBP) — -30.38; -20.15 mm Hg